LP
RANI icon

Longaeva Partners’s Rani Therapeutics RANI Stock Holding History

Longaeva Partners’s Portfolio RANI Stock Details RANI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.77M Hold
2,329,459
– – 0.04% 265
2026
Q1 		$1.71M Buy
2,329,459
+216,024
+10% +$276K 0.06% 156
2025
Q4 		$2.85M Buy
+2,113,435
New +$3.19M 0.24% 84

Other funds holding RANI

SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
AIC
AWM Investment Company New York $1.15B AUM 201.65% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $6.07B AUM 34.81% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
HCM
Heights Capital Management San Francisco, California $433M AUM 8.59% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Longaeva Partners's RANI Position: Q2 2026 in Review

Longaeva Partners held its Rani Therapeutics (RANI) position steady in Q2 2026 at 2,329,459 shares worth $1.77M. The position accounts for 0.04% of the portfolio, ranked #265.

Longaeva Partners first reported a position in RANI in Q4 2025 and has held it in 3 quarters since. The position peaked at $2.85M in Q4 2025. 68 funds tracked by Wall St. Rank hold RANI as of Q2 2026.

  • Longaeva Partners held 2,329,459 shares of Rani Therapeutics worth $1.77M as of Q2 2026.
  • Longaeva Partners left its Rani Therapeutics share count unchanged in Q2 2026.
  • Rani Therapeutics made up 0.04% of Longaeva Partners's portfolio in Q2 2026, its #265 holding.
  • Longaeva Partners first reported a position in Rani Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • Longaeva Partners's Rani Therapeutics position peaked at $2.85M in Q4 2025.
  • 68 funds tracked by Wall St. Rank held Rani Therapeutics as of Q2 2026.

Based on Longaeva Partners's 13F filing for Q2 2026, filed 14 Aug 2026.